Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Omalizumab biosimilar - Kashiv BioSciences

Next Previous
Drug Profile

Omalizumab biosimilar - Kashiv BioSciences

Alternative Names: ADL-018; AVT-23

Latest Information Update: 14 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Adello Biologics
  • Developer Alvotech; Amneal Pharmaceuticals; Kashiv BioSciences
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action IgE receptor antagonists; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Asthma

Highest Development Phases

  • Preregistration Asthma; Chronic urticaria; Food hypersensitivity; Rhinosinusitis

Most Recent Events

  • 06 Nov 2025 Efficacy and adverse events data from a phase III trial in Chronic Urticaria presented at the 2025 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI-2025)
  • 06 Oct 2025 The European Medicines Agency accepts Marketing Authorization Application for Omalizumab biosimilar for Rhinosinusitis, Asthma and Chronic-urticaria for review
  • 06 Oct 2025 Preregistration for Asthma in European Union (SC)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top